Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human C1 inhibitor (Ruconest) in pregnant women with preeclampsia
2018-002904-14Phase 2Terminated
- Sponsor
- Pharming Group
- Start
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of c1-esterase inhibitor in preeclampsia, sponsored by Pharming Group. Primary endpoint: Incidence and severity of adverse events. Started Oct 2018; status: terminated.
02
Drugs
c1-esterase inhibitor
03
Conditions
preeclampsia
Beyond the preview
Go deeper on 2018-002904-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002904-14.